We are live on
!
Find out more
BCAM
Boston Common Asset Management Portfolio holdings
AUM
$1.69B
1-Year Est. Return
28.29%
This Fund
S&P 500
This Quarter
Est. Return
+6.44%
1 Year Est. Return
+28.29%
3 Year Est. Return
+54.94%
5 Year Est. Return
+54.02%
10 Year Est. Return
+260.31%
AUM
$3.57B
AUM Growth
+$273M
(+8.3%)
Cap. Flow
-$19.8M
Cap. Flow
% of AUM
-0.56%
Top 10 Holdings %
Top 10 Hldgs %
15.41%
Holding
325
New
35
Increased
82
Reduced
162
Closed
28
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Quest Diagnostics
DGX
|
+$12.9M |
| 2 |
Salesforce
CRM
|
+$9.6M |
| 3 |
TSMC
TSM
|
+$9.22M |
| 4 |
KLA
KLAC
|
+$7.93M |
| 5 |
Eli Lilly
LLY
|
+$6.58M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Regeneron Pharmaceuticals
REGN
|
+$17.3M |
| 2 |
HOLX
Hologic
HOLX
|
+$16.8M |
| 3 |
Micron Technology
MU
|
+$10M |
| 4 |
Zimmer Biomet
ZBH
|
+$6.83M |
| 5 |
Ball Corp
BALL
|
+$6.55M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 52.06% |
| 2 | Technology | 13.67% |
| 3 | Financials | 8.97% |
| 4 | Healthcare | 5.78% |
| 5 | Communication Services | 4.96% |
Similar funds
KFGK
CWG
MCM
AFM
BW
GAI
TP
Boston Common Asset Management's Q2 2025 Portfolio in Review
As of Q2 2025, Boston Common Asset Management held 325 positions worth $3.57B, up 8.3% from $3.29B the previous quarter. Its ten largest holdings account for 15% of the portfolio.
Boston Common Asset Management's Q2 2025 filing shows 35 new, 82 increased, 162 reduced and 28 closed positions. Its largest new stake was Quest Diagnostics: 74,250 shares worth $13.3M. The largest sale was Regeneron Pharmaceuticals, an estimated $17.3M.
By sector, the portfolio is most concentrated in Miscellaneous at 52% of assets, up from 50% a quarter earlier, followed by Technology and Financials.
- Boston Common Asset Management's largest Q2 2025 buy was Quest Diagnostics: 74,250 shares worth $13.3M.
- Boston Common Asset Management added most to Salesforce in Q2 2025, an estimated $9.6M increase.
- Boston Common Asset Management's biggest Q2 2025 reduction was Micron Technology, cutting an estimated $10M.
- Boston Common Asset Management fully exited Regeneron Pharmaceuticals in Q2 2025, selling an estimated $17.3M.
- Boston Common Asset Management's ten largest holdings make up 15% of its $3.57B portfolio in Q2 2025.
- Boston Common Asset Management opened 35 new positions and closed 28 in Q2 2025.
- Boston Common Asset Management's portfolio value rose 8.3% quarter-over-quarter to $3.57B.
Based on Boston Common Asset Management's 13F filing for Q2 2025, filed 22 Jul 2025.